Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
TARRYTOWN, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on M...
Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders....
Prestige Consumer Healthcare Inc (NYSE:PBH ) Q4 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Phil Terpolilli - Director of Investor Relations Ron Lombardi - Chairman, Pres...
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compa...
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.07 per share a year ago...
TARRYTOWN, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2024....
Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14....
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have perfo...
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two companies is the best option for ...
